Cold Atmospheric Plasma Device Extension Study

Status Recruiting

Clinical Trial Summary

Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05937672
Study type	Interventional
Source	Medical University of South Carolina
Contact	Courtney Linkous, BA
Phone	843-566-2453
Email	linkousc@musc.edu
Status	Recruiting
Phase	Phase 3
Start date	September 18, 2023
Completion date	August 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03017846` - Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2	Phase 2
Completed	`NCT04535531` - A Phase 3 Molluscum Contagiosum Efficacy and Safety Study	Phase 3
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A
Completed	`NCT05897112` - Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum	Phase 1
Withdrawn	`NCT05536882` - MC RCT - BPO vs Adapalene	Phase 3
Completed	`NCT03377790` - Cantharidin Application in Molluscum Patients-1	Phase 3
Completed	`NCT01348386` - Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum	Phase 2/Phase 3
Completed	`NCT05634460` - Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum	Phase 1
Completed	`NCT03186378` - Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.	Phase 2
Completed	`NCT03927716` - A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)	Phase 3
Recruiting	`NCT04476186` - The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children	N/A
Completed	`NCT03927703` - A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC	Phase 3
Completed	`NCT02665260` - Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum	Phase 2
Completed	`NCT03436615` - A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum	Phase 2
Recruiting	`NCT02759900` - Using a Cold Atmospheric Plasma Device to Treat Skin Disorders	N/A
Completed	`NCT05680181` - Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
Completed	`NCT03077750` - A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum	Phase 2
Terminated	`NCT02024581` - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum	Phase 2
Completed	`NCT03377803` - Cantharidin Application in Molluscum Patients	Phase 3
Withdrawn	`NCT03336372` - Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients	Early Phase 1